These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 21615738)

  • 1. Tracking extranigral degeneration in animal models of Parkinson's disease: quest for effective therapeutic strategies.
    Knaryan VH; Samantaray S; Le Gal C; Ray SK; Banik NL
    J Neurochem; 2011 Aug; 118(3):326-38. PubMed ID: 21615738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extranigral neurodegeneration in Parkinson's disease.
    Samantaray S; Butler JT; Ray SK; Banik NL
    Ann N Y Acad Sci; 2008 Oct; 1139():331-6. PubMed ID: 18991878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-motor extranigral signs and symptoms in Parkinson's disease.
    Wolters ECh
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S6-12. PubMed ID: 20083010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post mortem studies in Parkinson's disease--is it possible to detect brain areas for specific symptoms?
    Jellinger KA
    J Neural Transm Suppl; 1999; 56():1-29. PubMed ID: 10370901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview of the extranigral aspects of Parkinson disease.
    Lim SY; Fox SH; Lang AE
    Arch Neurol; 2009 Feb; 66(2):167-72. PubMed ID: 19204152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
    Shin E; Rogers JT; Devoto P; Björklund A; Carta M
    Exp Neurol; 2014 Jul; 257():25-38. PubMed ID: 24747357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nigral and extranigral pathology in Parkinson's disease.
    Braak H; Braak E; Yilmazer D; Schultz C; de Vos RA; Jansen EN
    J Neural Transm Suppl; 1995; 46():15-31. PubMed ID: 8821039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. When does Parkinson's disease begin? From prodromal disease to motor signs.
    Meissner WG
    Rev Neurol (Paris); 2012 Nov; 168(11):809-14. PubMed ID: 22981298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parkinson's disease and alpha-synucleinopathies: from arising pathways to therapeutic challenge.
    Miraglia F; Betti L; Palego L; Giannaccini G
    Cent Nerv Syst Agents Med Chem; 2015; 15(2):109-16. PubMed ID: 25896035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-oxidant polydatin (piceid) protects against substantia nigral motor degeneration in multiple rodent models of Parkinson's disease.
    Chen Y; Zhang DQ; Liao Z; Wang B; Gong S; Wang C; Zhang MZ; Wang GH; Cai H; Liao FF; Xu JP
    Mol Neurodegener; 2015 Mar; 10():4. PubMed ID: 26013581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
    Fleming SM; Delville Y; Schallert T
    Behav Brain Res; 2005 Jan; 156(2):201-13. PubMed ID: 15582106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Calpain Activation Protects MPTP-Induced Nigral and Spinal Cord Neurodegeneration, Reduces Inflammation, and Improves Gait Dynamics in Mice.
    Samantaray S; Knaryan VH; Shields DC; Cox AA; Haque A; Banik NL
    Mol Neurobiol; 2015 Oct; 52(2):1054-66. PubMed ID: 26108182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Critical role of calpain in spinal cord degeneration in Parkinson's disease.
    Samantaray S; Knaryan VH; Shields DC; Banik NL
    J Neurochem; 2013 Dec; 127(6):880-90. PubMed ID: 23875735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An order in Lewy body disorders: Retrograde degeneration in hyperbranching axons as a fundamental structural template accounting for focal/multifocal Lewy body disease.
    Uchihara T
    Neuropathology; 2017 Apr; 37(2):129-149. PubMed ID: 27862327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroinflammation and α-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease.
    Gao HM; Zhang F; Zhou H; Kam W; Wilson B; Hong JS
    Environ Health Perspect; 2011 Jun; 119(6):807-14. PubMed ID: 21245015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
    Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
    Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers of Parkinson's disease: present and future.
    Miller DB; O'Callaghan JP
    Metabolism; 2015 Mar; 64(3 Suppl 1):S40-6. PubMed ID: 25510818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parkinson's disease as a multisystem disorder.
    Klingelhoefer L; Reichmann H
    J Neural Transm (Vienna); 2017 Jun; 124(6):709-713. PubMed ID: 28155133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuropathological Staging of Brain Pathology in Sporadic Parkinson's disease: Separating the Wheat from the Chaff.
    Braak H; Del Tredici K
    J Parkinsons Dis; 2017; 7(s1):S71-S85. PubMed ID: 28282810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. L-DOPA: a scapegoat for accelerated neurodegeneration in Parkinson's disease?
    Lipski J; Nistico R; Berretta N; Guatteo E; Bernardi G; Mercuri NB
    Prog Neurobiol; 2011 Sep; 94(4):389-407. PubMed ID: 21723913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.